2023: Oct 09
Modiblast has got confirmed an extension of qualification “INVEST – Zuschuss für Wagniskapital” by BaFA until 12th Oct 2024.
2023: Jul 30
Modiblast will have a presence at the shared booth of Bayern Innovativ / BioM at BioEurope on 6th – 8th November 2023 in Munich: https://informaconnect.com/bioeurope/
2023: May 17
#Modiblast has become a clinical phase company!
Recently we reached an important clinical development milestone: the #ScientificAdvice hearing at #BfArM (German Federal Institute for Drugs and Medical Devices) was passed without objections, significantly increasing the chances to get final regulatory approval for the planned Phase 1/2 clinical trial of our in vivo AML and MDS immunotherapy #MB101. All safety aspects are sufficiently taken into account, the preclinical data were deemed adequate and the study rationale well substantiated. Once funding of the study is secured, we will work out the detailed protocol and sign contracts with the CRO and study centers.
2022: Dec 27
We are proud about the latest research publication by our CEO/CSO Helga Schmetzer and her team about leukemia derived Dendritic Cells immune activation in a renowned international journal: https://www.mdpi.com/1422-0067/24/1/463
2022: Aug 04
A new publication by the research team around our CEO Helga has been accepted and published in Clinical Immunology Volume 242, September 2022
Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia
• Immunomodulatory kits generating leukaemia-derived-dendritic-cells do not induce blast proliferation ex vivo in most cases.
• Leukaemia-derived-dendritic-cells’ induced anti-leukaemic activity can compensate induced blast proliferation.
• IPO-38 is a sensitive marker to quantify proliferating blasts.
2022: Jun 08
The latest paper of our Chief Scientist Helga Schmetzer and her team “Leukemia derived dendritic cell (DCleu) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells” has been accepted by Immunobiology (Elsevier) for publication later.
2022: Apr 26
Modiblast is prominently featured in the German startupdetector report 2021 on p. 47 among the startups with the most female angels: https://startupdetector.de/reports/startupdetector-report-2021.pdf
2022: Mar 16
Relaunch of Webpage.
2021: Dec 16
BfArM kickoff meeting for the clinical study (VALID = “Vaccination against leukemia by in vivo differentiation of blasts”) sponsored by University of Augsburg and supported by Modiblast.
2021 Oct 19-21
2021 Oct 01
2021 Apr 19
We are proud to announce that PD Dr. med. Behrouz Mansouri has joined our team as Medical Director. Behrouz is a renowned expert in Transfusion Medicine and Hematology, has been awarded the “Volkmar Sachs Medal” by the German Society for Transfusion Medicine (DGTI). His tasks will be planning and coordinating our clinical study activities, liaison with patient representative organizations, and taking care of public relations in the regarding clinical affairs as well as scientific and non-scientific areas.
2021 Feb 09
2020 Mar 11
2020 Jan 24
Modiblast Pharma GmbH is founded in Oberhaching near Munich.
2017 Feb 01